Growth suppression by p16ink4 requires functional retinoblastoma protein

R H Medema, R E Herrera, F Lam, R A Weinberg, R H Medema, R E Herrera, F Lam, R A Weinberg

Abstract

p16ink4 has been implicated as a tumor suppressor that is lost from a variety of human tumors and human cell lines. p16ink4 specifically binds and inhibits the cyclin-dependent kinases 4 and 6. In vitro, these kinases can phosphorylate the product of the retinoblastoma tumor suppressor gene. Thus, p16ink4 could exert its function as tumor suppressor through inhibition of phosphorylation and functional inactivation of the retinoblastoma protein. Here we show that overexpression of p16ink4 in certain cell types will lead to an arrest in the G1 phase of the cell cycle. In addition, we show that p16ink4 can only suppress the growth of human cells that contain functional pRB. Moreover, we have compared the effect of p16ink4 expression on embryo fibroblasts from wild-type and RB homozygous mutant mice. Wild-type embryo fibroblasts are inhibited by p16ink4, whereas the RB nullizygous fibroblasts are not. These data not only show that the presence of pRB is crucial for growth suppression by p16ink4 but also indicate that the pRB is the critical target acted upon by cyclin D-dependent kinases in the G1 phase of the cell cycle.

References

    1. Genes Dev. 1993 Mar;7(3):331-42
    1. Science. 1995 Jan 13;267(5195):249-52
    1. Genes Dev. 1993 Jul;7(7A):1111-25
    1. Genes Dev. 1993 Aug;7(8):1572-83
    1. Cancer Res. 1993 Nov 15;53(22):5535-41
    1. Cell. 1993 Nov 19;75(4):805-16
    1. Nature. 1993 Dec 16;366(6456):701-4
    1. Nature. 1993 Dec 16;366(6456):704-7
    1. Nature. 1993 Dec 16;366(6456):707-10
    1. Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):709-13
    1. Oncogene. 1994 Mar;9(3):707-18
    1. Mol Cell Biol. 1994 Mar;14(3):2077-86
    1. Curr Biol. 1995 Jan 1;5(1):28-31
    1. Mol Cell Biol. 1995 May;15(5):2612-24
    1. Nature. 1994 Apr 21;368(6473):753-6
    1. Science. 1994 Apr 15;264(5157):436-40
    1. Oncogene. 1994 Jun;9(6):1633-40
    1. Nature. 1994 Jun 16;369(6481):574-8
    1. Cancer Res. 1994 Aug 15;54(16):4299-303
    1. EMBO J. 1994 Jul 15;13(14):3329-38
    1. Methods Enzymol. 1980;65(1):826-39
    1. J Exp Med. 1988 Jun 1;167(6):1975-80
    1. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6460-4
    1. Nucleic Acids Res. 1990 Jun 25;18(12):3587-96
    1. Oncogene. 1990 Jul;5(7):973-80
    1. Science. 1990 Aug 24;249(4971):912-5
    1. Nature. 1991 Apr 11;350(6318):512-5
    1. Mol Cell Biol. 1991 Oct;11(10):4846-53
    1. Science. 1991 Nov 22;254(5035):1138-46
    1. Genomics. 1992 Jul;13(3):565-74
    1. Genomics. 1992 Jul;13(3):575-84
    1. Cell. 1992 Sep 18;70(6):993-1006
    1. Nature. 1992 Sep 24;359(6393):295-300
    1. Oncogene. 1994 Sep;9(9):2663-74
    1. Nature. 1994 Sep 15;371(6494):257-61
    1. Oncogene. 1994 Nov;9(11):3375-8
    1. Cancer Res. 1994 Nov 15;54(22):5816-20
    1. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11045-9
    1. Cancer Res. 1994 Dec 15;54(24):6321-4
    1. Genes Dev. 1994 Dec 15;8(24):2939-52
    1. Cell. 1993 Jun 18;73(6):1059-65

Source: PubMed

3
Předplatit